New Delhi, May 13 -- India's generics medicine industry is unlikely to be impacted by President Donald Trump's move to slash drug prices in the US drastically, said Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA).

On Monday, President Trump signed an Executive Order, which he termed as one of the "most consequential Executive Orders" in the country's history. The order directed pharmaceutical companies to lower the prices of their medicines to align with what other countries pay for such prescription medicines.

Trump gave pharmaceutical companies a 30-day deadline to cut costs or face action.

"The generics industry is unlikely to be impacted, as it operates on razor-thin margins. In the US, the generics industry...